Developer docs
API playgroundTry for free, no card

Search company profiles

TRIUMF Innovations

Full company profile

uuid000mi4f

Namestring
TRIUMF Innovations
Legal namestring
TRIUMF Innovations Inc.
Company typeenum
Private
Founded yearint
2008
Descriptiontext

TRIUMF Innovations Inc. is a private Vancouver-based company (founded 2008, mandate expanded April 2017) that operates as the commercialization arm of TRIUMF, Canada's national particle accelerator laboratory. It links cutting-edge particle-physics research to commercial markets through three channels: technology licensing, industry partnerships, and company creation from a portfolio of five spin-offs (ARTMS, Ideon, Micromatter, IKOMED, and D-Pace). Its core technology is built on TRIUMF's particle accelerator infrastructure, including the 520 MeV cyclotron (the largest in the world) and the TR-24 medical cyclotron at the IAMI facility, supporting medical isotope production (Tc-99m, Ga-68, Cu-64, Zr-89, Ac-225, F-18), proton/neutron irradiation testing services for aerospace electronics, neutron spectrometry for fusion diagnostics, and cosmic-ray muon tomography for mineral exploration. The IP and know-how base, partially cGMP-certified, includes the QUANTM Irradiation System licensed to ARTMS, muon-detection systems licensed to Ideon, and accelerator components licensed to D-Pace, all originally developed within TRIUMF's ~600-person research environment.

TRIUMF Innovations monetizes through a mix of licensing and royalty streams on out-licensed TRIUMF technologies, fee-for-service irradiation testing via the PIF/NIF facilities, professional services tied to industry R&D collaborations, management oversight of the CMIE Development Fund (backed by a $35M CAD Strategic Innovation Fund award), and equity participation in spin-off companies. Customer segments span hospitals and radiopharmaceutical firms (medical isotope demand), aerospace and defense companies (radiation-hardness testing), mining and natural resources firms (muon tomography), fusion energy companies (plasma diagnostics), and research institutions. Notable counterparties include MDA Robotics, Fusion Pharmaceuticals, Canadian Nuclear Laboratories, BWXT Medical, GE Healthcare, General Fusion, Telix Pharmaceuticals, Deerfield Management, and Quark Venture. The 18% of TRIUMF funding derived from commercialization activities, $52M raised across the five spin-offs, the $82.5M USD Telix/ARTMS exit, and a $400M federal capital infusion into the parent lab in 2024 underscore the scale and strategic significance of the commercialization platform.

Short descriptiontext

TRIUMF Innovations is the private commercialization arm of TRIUMF, Canada's national particle accelerator laboratory, licensing accelerator-based technologies and creating spin-off companies in medical isotopes, radiation testing, and muon tomography for global industry and research partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersVancouver, Canada
HQ citystring
Vancouver
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical isotope production, technology commercialization, radiation testing services, particle accelerator applications, spin-off company creation
Industry6 codes
PRIMARYHLAIAGAD
Radioisotope Production (Reactor/Cyclotron/Gamma)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYEUAKAIAA
Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYEUAKAIAL
Nuclear Materials Testing, Assay & Characterization Services (NDA/NDE, radiochemistry, materials analysis)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYEUAKAIAK
Radiation Detection Instruments & Systems (Portal monitors, spectrometers, contamination monitors)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYHLAIAGAG
Nuclear Medicine Imaging Agents & Kits (Cold Kits/Precursors)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAJAI
Radiopharmaceutical & Nuclear Medicine Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
NAICS code4 codes
  • Testing Laboratories and Services54138
  • Irradiation Apparatus Manufacturing334517
  • Chemical Manufacturing325
  • Medical Laboratories621511
SIC code5 codes
  • Services-Commercial Physical & Biological Research8731
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Testing Laboratories8734
  • X-Ray Apparatus & Tubes & Related Irradiation Apparatus3844
  • Chemicals & Allied Products2800
Product category
Technology Commercialization and Particle Accelerator-Based Research Services
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model5 records
1Technology Licensing and IP Management
TypeLicensing Royalties
Description

Out-licensing TRIUMF technologies, providing technology transfer and licensing services to partner research institutions and industry

triumfinnovations.ca
2Company Creation and Spin-offs
TypeOne Time License
Description

Creating and supporting spin-off companies from TRIUMF technologies. Five successful spin-offs created (ARTMS, Ideon, Micromatter, IKOMED, D-Pace) with $52 million in seed and Series A & B financing raised

triumfinnovations.ca
3Industry Partnerships and Collaborations
TypeProfessional Services
Description

Facilitating industry partnerships between TRIUMF researchers and private sector companies for joint R&D, product development, and commercialization

triumfinnovations.ca
4Irradiation Testing Services
TypeProfessional Services
Description

Commercial irradiation services for electronics testing simulating space and terrestrial radiation environments, with commercial revenue increased by over 400% in recent years

triumfinnovations.ca
5Federal and Provincial Funding
TypeSubscription Recurring
Description

Government funding including $35 million from Strategic Innovation Fund for CMIE, $400 million federal investment in TRIUMF, and various NSERC grants. 18% of TRIUMF's funding comes from commercialization activities

triumfinnovations.ca
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

TRIUMF Innovations commercializes particle-accelerator-based technologies developed at TRIUMF, Canada's national particle accelerator laboratory. It does so through technology licensing, spin-off company creation and equity oversight, fee-based irradiation and medical isotope production services using TRIUMF's cyclotrons and Proton/Neutron Irradiation Facilities, and the Canadian Medical Isotope Ecosystem (CMIE) national platform that channels federal funding into radiopharmaceutical development. Its customer base consists of radiopharmaceutical companies, hospitals with medical cyclotrons, aerospace and electronics firms needing radiation testing, mining exploration companies, and fusion energy developers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 5 successful spin-off companies created with $52M in financing raised
+3 more records
Product overview1 text field

TRIUMF Innovations serves as the commercialization arm of TRIUMF, Canada's national particle accelerator laboratory, operating a multi-faceted portfolio of products and services. The core offerings include medical isotope production via cyclotron facilities (TR-24 Medical Cyclotron, F-18, C-11, Ac-225, Sr-82, Ge-68, I-123), Irradiation Testing Services (proton and neutron beam testing for electronics), and the Canadian Medical Isotope Ecosystem (CMIE) development initiative. The portfolio also includes five successful spin-off companies: ARTMS QUANTM Irradiation System (cyclotron-based medical isotope production), Ideon Muon Tomography Platform (AI-powered subsurface imaging), Micromatter Target Foils, IKOMED AI-Guided X-ray Systems, and D-Pace Accelerator Components. The organization also provides neutron spectrometer technology for fusion diagnostics and entrepreneurship training programs through UBC partnership.

Product and service10 records
1TR-24 Medical Cyclotron
CategoryMedical Isotope Production
Description

State-of-the-art commercial cyclotron at the Institute for Advanced Medical Isotopes (IAMI) producing medical isotopes critical for Canadian health research and clinical use, including Ac-225. For radiopharmaceutical developers and clinical researchers.

2Cyclotron Isotope Production (F-18, C-11, Ac-225, Sr-82, Ge-68, I-123)
CategoryMedical Isotope Production
Description

Production of radioisotopes using TRIUMF's 13 MeV and 24 MeV cyclotrons for PET and SPECT scans, and the 520 MeV cyclotron for targeted alpha therapy applications. For radiopharmaceutical developers, hospitals, and clinical researchers.

3Irradiation Testing Services (PIF & NIF)
CategoryRadiation Testing Services
Description

Proton and Neutron Irradiation Facilities (PIF & NIF) providing low-intensity energetic proton and neutron beams to simulate radiation exposures for accelerated testing of electronics in space, air, or ground environments. For aerospace and electronics manufacturers.

4ARTMS QUANTM Irradiation System
CategoryMedical Isotope Production Technology
Description

Technology enabling hospitals to use existing medical cyclotrons for production of medical isotopes including Technetium-99m, Gallium-68, Copper-64, and Zirconium-89 for diagnostic imaging. For hospitals with medical cyclotrons and radiopharmaceutical manufacturers.

5Ideon Muon Tomography Platform
CategorySubsurface Imaging Technology
Description

World-first discovery platform using cosmic-ray muon tomography with proprietary detectors, imaging systems, and AI to provide subsurface imaging up to 1 km depth for mineral exploration. For mining and mineral exploration companies.

6Micromatter Target Foils
CategoryAccelerator Components and Standards
Description

Thin carbon foils, accelerator target foils, and X-ray fluorescence calibration standards with applications in air quality monitoring, trace element detection, and particle accelerators. For research labs and accelerator operators.

7IKOMED AI-Guided X-ray Systems
CategoryMedical Device Technology
Description

AI-guided X-ray shuttering system protecting patients and medical staff during minimally-invasive procedures, and in-development device for emphysema treatment using radiofrequency. For hospitals and surgical centers.

8D-Pace Accelerator Components
CategoryAccelerator Components and Systems
Description

Beamline systems, beam diagnostic devices, and ion sources for research, industrial, and commercial accelerator systems, providing H-, D-, C2-, and other ions. For accelerator manufacturers and operators.

9Canadian Medical Isotope Ecosystem (CMIE) Development Fund
CategoryIndustry Consortium and Funding Program
Description

Nation-wide initiative co-led with Centre for Probe Development and Commercialization, backed by up to $35M from Strategic Innovation Fund to unite stakeholders and accelerate medical isotope technology development and commercialization through the CMIE Development Fund. For Canadian startups, research institutions, and industry partners in medical isotopes.

10Ultra-fast Neutron Spectrometer System
CategoryFusion Diagnostic Instrumentation
Description

Ultra-fast neutron spectrometer system developed with General Fusion to measure plasma temperatures at fusion conditions over 100 million degrees Celsius, tagging neutron interactions every nanosecond. For fusion energy developers.

Scale indicator17 records

Each record includes

Type, Value, Description, Source

Partnership18 partners
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2024-03-27
Description

NSERC Alliance grant collaboration to develop ultra-fast neutron spectrometer system for General Fusion's LM26 fusion demonstration machine. $800,000 over four years to measure plasma temperatures at fusion conditions exceeding 100 million degrees Celsius.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-03-27
Description

Partner in neutron spectrometer project with General Fusion, designing and implementing a dedicated neutron test facility at TRIUMF.

3Université de Sherbrooke
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-03-27
Description

Developing and fabricating new Canadian single photon detection technology for the upgraded neutron spectrometer system to be installed on General Fusion's near-commercial machine.

triumfinnovations.ca
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-03-11
Description

Telix Pharmaceuticals acquired ARTMS Inc. for $82.5M USD, including ARTMS' advanced cyclotron-based isotope production platform, manufacturing plant, and stockpile of ultra-pure rare metals. This is the largest acquisition of a TRIUMF spin-off company.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-27
Description

Co-leading the Canadian Medical Isotope Ecosystem (CMIE), a national platform backed by $35 million from the Strategic Innovation Fund. CMIE aims to advance medical isotope production, R&D investment, collaboration, technology adoption, and training to enable Canada to lead in medical isotope innovation.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-27
Description

CMIE partner providing infrastructure and support for medical isotope production and development in Canada.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-27
Description

CMIE partner with McMaster Nuclear Reactor as part of national platform to accelerate medical isotope development in Canada.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2023-03-10
Description

MOU with Canadian-German nuclear technology company to advance Small Modular Reactor (SMR) development based on Dual Fluid technology. Collaboration leverages TRIUMF's Proton and Neutron Irradiation Facilities and metallurgical testing capabilities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-12-16
Description

Collaboration for development, production, and supply of actinium-225. Fusion provides funding for TRIUMF to upgrade Ac-225 production infrastructure; receives preferred access and pricing to the resulting isotope for use in their radiopharmaceutical development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-04-02
Description

Partnership to advance and commercialize promising research in novel radiopharmaceuticals. Combines R&D, manufacturing, and commercialization strengths to develop innovative personalized cancer treatments using targeted alpha therapy.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-09-27
Description

Strategic partnership for production of actinium-225, a rare medical isotope with potential for groundbreaking cancer therapies. TRIUMF produces Ac-225 using its high-energy cyclotron; CNL processes it at Chalk River Laboratories. Successfully completed first joint production run in October 2019.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-09-10
Description

ARTMS partnered with GE Healthcare around the QUANTM99 Irradiation System for radioisotope production. Partnership includes installation of Europe's first QUANTM system and research into expanding isotopes on GE's PETtrace 800 platform of medical cyclotrons.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Commercial agreements for production and supply of actinium-225 ('the rarest drug on earth') to researchers and patients around the world.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

ARTMS partnered with ImaginAb for innovative manufacture of 89Zr CD8 ImmunoPET agent using ARTMS' high-power technology to enhance production of ImaginAb's proprietary antibody.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

ARTMS collaboration with POINT Biopharma and Canadian Molecular Imaging Probe Consortium for Health Canada submission on Gallium-68 production.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

TRIUMF joined CNIC to strengthen national capacity in radioisotope and radiopharmaceutical research and education, and to advance benefits of medical isotopes in diagnosing and treating life-threatening illnesses.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Electromagnet manufacturer purchased 50% stake in D-Pace in 2014, enabling collaboration that has developed and commercialized approximately a dozen new products for the particle accelerator market.

18University of British Columbia
Strategic tierCoreTypeStrategic or Co-development Partner
Description

TRIUMF is hosted on UBC campus; partnered with UBC and BC Cancer for Institute for Advanced Medical Isotopes (IAMI) development. TRIUMF is a joint venture owned by 21 member universities.

triumfinnovations.ca
Recent move12 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Canada's federal nuclear science laboratory and a core strategic partner on Ac-225 production. CNL operates Chalk River Laboratories and collaborates with TRIUMF on actinium-225 processing — a comparable government nuclear research entity engaged in isotope production and nuclear materials R&D.

TypeDirect peer
Description

TRIUMF Innovations' largest spin-off, founded by TRIUMF scientists, commercializing the QUANTM Irradiation System for cyclotron-based medical isotope production. Acquired by Telix Pharmaceuticals in March 2024 for $82.5M USD; provides the closest internal benchmark for TI's commercialization outcomes.

TypeDirect peer
Description

TRIUMF spin-off commercializing cosmic-ray muon tomography with AI for subsurface mineral exploration. Directly comparable as a TI-incubated company demonstrating the same commercialization model applied to a non-medical vertical.

TypeDirect peer
Description

U.S.-based medical isotope producer using alternative production routes (fusion-based neutron generators) to address Tc-99m and other isotope shortages. Directly comparable mission — solving medical isotope supply chain vulnerability — and a direct competitor to TI/ARTMS technology.

TypeDirect peer
Description

U.S. commercial medical isotope producer focused on non-uranium-based Mo-99/Tc-99m production. Directly comparable as a privately-held commercial-stage medical isotope producer targeting the same supply-chain-replacement opportunity that ARTMS was built to address.

TypeBroad incumbent
Description

Global radiopharmaceutical company and acquirer of ARTMS. While much larger and focused on finished radiopharmaceuticals rather than isotope production technology, Telix represents the strategic acquirer/customer archetype that TI's spin-offs increasingly interact with as commercial-stage entities.

TypeBroad incumbent
Description

Global medical imaging and cyclotron manufacturer; ARTMS' QUANTM system integrates onto GE's PETtrace 800 platform, making GE both partner and incumbent competitor with substantially greater scale in PET/SPECT imaging infrastructure.

8IBA (Ion Beam Applications)
TypeBroad incumbent
Description

Belgian global leader in cyclotron manufacturing, proton therapy, and radioisotope production. Operates in the same isotope production and accelerator technology space as TRIUMF/D-Pace but with substantially greater commercial scale and global footprint.

TypeBroad incumbent
Description

U.S. nuclear technology manufacturer with a medical isotopes division (BWXT Medical) that is a commercial partner of TRIUMF Innovations on Ac-225 supply. Comparable as an incumbent in nuclear medicine isotopes and a customer/competitor in sealed source manufacturing.

10Cyclotek
TypeRegional player
Description

Australian radiopharmaceutical manufacturer producing PET and SPECT tracers using cyclotrons. Comparable as a privately-held regional radiopharma producer, though operating in a different geography from TRIUMF Innovations.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TRIUMF Innovations

Technology Commercialization and Particle Accelerator-Based Research Servicestriumfinnovations.ca

TRIUMF Innovations is the private commercialization arm of TRIUMF, Canada's national particle accelerator laboratory, licensing accelerator-based technologies and creating spin-off companies in medical isotopes, radiation testing, and muon tomography for global industry and research partners.

What TRIUMF Innovations does

TRIUMF Innovations Inc. is a private Vancouver-based company (founded 2008, mandate expanded April 2017) that operates as the commercialization arm of TRIUMF, Canada's national particle accelerator laboratory. It links cutting-edge particle-physics research to commercial markets through three channels: technology licensing, industry partnerships, and company creation from a portfolio of five spin-offs (ARTMS, Ideon, Micromatter, IKOMED, and D-Pace). Its core technology is built on TRIUMF's particle accelerator infrastructure, including the 520 MeV cyclotron (the largest in the world) and the TR-24 medical cyclotron at the IAMI facility, supporting medical isotope production (Tc-99m, Ga-68, Cu-64, Zr-89, Ac-225, F-18), proton/neutron irradiation testing services for aerospace electronics, neutron spectrometry for fusion diagnostics, and cosmic-ray muon tomography for mineral exploration. The IP and know-how base, partially cGMP-certified, includes the QUANTM Irradiation System licensed to ARTMS, muon-detection systems licensed to Ideon, and accelerator components licensed to D-Pace, all originally developed within TRIUMF's ~600-person research environment.

TRIUMF Innovations monetizes through a mix of licensing and royalty streams on out-licensed TRIUMF technologies, fee-for-service irradiation testing via the PIF/NIF facilities, professional services tied to industry R&D collaborations, management oversight of the CMIE Development Fund (backed by a $35M CAD Strategic Innovation Fund award), and equity participation in spin-off companies. Customer segments span hospitals and radiopharmaceutical firms (medical isotope demand), aerospace and defense companies (radiation-hardness testing), mining and natural resources firms (muon tomography), fusion energy companies (plasma diagnostics), and research institutions. Notable counterparties include MDA Robotics, Fusion Pharmaceuticals, Canadian Nuclear Laboratories, BWXT Medical, GE Healthcare, General Fusion, Telix Pharmaceuticals, Deerfield Management, and Quark Venture. The 18% of TRIUMF funding derived from commercialization activities, $52M raised across the five spin-offs, the $82.5M USD Telix/ARTMS exit, and a $400M federal capital infusion into the parent lab in 2024 underscore the scale and strategic significance of the commercialization platform.

TRIUMF Innovations firmographics

Firmographics
Name
TRIUMF Innovations
Legal name
TRIUMF Innovations Inc.
Website
https://triumfinnovations.ca
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
1–10 employees
Short description
TRIUMF Innovations is the private commercialization arm of TRIUMF, Canada's national particle accelerator laboratory, licensing accelerator-based technologies and creating spin-off companies in medical isotopes, radiation testing, and muon tomography for global industry and research partners.
Ownership category
akta.pro rank

TRIUMF Innovations industry classification

Industry
Product category
Technology Commercialization and Particle Accelerator-Based Research Services
NAICS
Testing Laboratories and Services (54138), Irradiation Apparatus Manufacturing (334517), Chemical Manufacturing (325), Medical Laboratories (621511)
SIC
Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835), Services-Testing Laboratories (8734), X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844), Chemicals & Allied Products (2800)
akta.pro industry
PRIMARYHLAIAGAD
Radioisotope Production (Reactor/Cyclotron/Gamma)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYEUAKAIAA
Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYEUAKAIAL
Nuclear Materials Testing, Assay & Characterization Services (NDA/NDE, radiochemistry, materials analysis)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYEUAKAIAK
Radiation Detection Instruments & Systems (Portal monitors, spectrometers, contamination monitors)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYHLAIAGAG
Nuclear Medicine Imaging Agents & Kits (Cold Kits/Precursors)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAJAI
Radiopharmaceutical & Nuclear Medicine Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling

Keywords

  • Medical isotope production
  • Technology commercialization
  • Radiation testing services
  • Particle accelerator applications
  • Spin-off company creation

Where TRIUMF Innovations is headquartered

Location

Headquarters

HQ city
Vancouver
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

TRIUMF Innovations business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Others

Revenue model

  1. Technology Licensing and IP Management: Out-licensing TRIUMF technologies, providing technology transfer and licensing services to partner research institutions and industry
  2. Company Creation and Spin-offs: Creating and supporting spin-off companies from TRIUMF technologies. Five successful spin-offs created (ARTMS, Ideon, Micromatter, IKOMED, D-Pace) with $52 million in seed and Series A & B financing raised
  3. Industry Partnerships and Collaborations: Facilitating industry partnerships between TRIUMF researchers and private sector companies for joint R&D, product development, and commercialization
  4. Irradiation Testing Services: Commercial irradiation services for electronics testing simulating space and terrestrial radiation environments, with commercial revenue increased by over 400% in recent years
  5. Federal and Provincial Funding: Government funding including $35 million from Strategic Innovation Fund for CMIE, $400 million federal investment in TRIUMF, and various NSERC grants. 18% of TRIUMF's funding comes from commercialization activities

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

TRIUMF Innovations product offering

Product offering

Core offering

TRIUMF Innovations commercializes particle-accelerator-based technologies developed at TRIUMF, Canada's national particle accelerator laboratory. It does so through technology licensing, spin-off company creation and equity oversight, fee-based irradiation and medical isotope production services using TRIUMF's cyclotrons and Proton/Neutron Irradiation Facilities, and the Canadian Medical Isotope Ecosystem (CMIE) national platform that channels federal funding into radiopharmaceutical development. Its customer base consists of radiopharmaceutical companies, hospitals with medical cyclotrons, aerospace and electronics firms needing radiation testing, mining exploration companies, and fusion energy developers.

Product overview

TRIUMF Innovations serves as the commercialization arm of TRIUMF, Canada's national particle accelerator laboratory, operating a multi-faceted portfolio of products and services. The core offerings include medical isotope production via cyclotron facilities (TR-24 Medical Cyclotron, F-18, C-11, Ac-225, Sr-82, Ge-68, I-123), Irradiation Testing Services (proton and neutron beam testing for electronics), and the Canadian Medical Isotope Ecosystem (CMIE) development initiative. The portfolio also includes five successful spin-off companies: ARTMS QUANTM Irradiation System (cyclotron-based medical isotope production), Ideon Muon Tomography Platform (AI-powered subsurface imaging), Micromatter Target Foils, IKOMED AI-Guided X-ray Systems, and D-Pace Accelerator Components. The organization also provides neutron spectrometer technology for fusion diagnostics and entrepreneurship training programs through UBC partnership.

Differentiator

Problem solved

Functional benefit

Products and services

  • TR-24 Medical Cyclotron State-of-the-art commercial cyclotron at the Institute for Advanced Medical Isotopes (IAMI) producing medical isotopes critical for Canadian health research and clinical use, including Ac-225. For radiopharmaceutical developers and clinical researchers.
  • Cyclotron Isotope Production (F-18, C-11, Ac-225, Sr-82, Ge-68, I-123) Production of radioisotopes using TRIUMF's 13 MeV and 24 MeV cyclotrons for PET and SPECT scans, and the 520 MeV cyclotron for targeted alpha therapy applications. For radiopharmaceutical developers, hospitals, and clinical researchers.
  • Irradiation Testing Services (PIF & NIF) Proton and Neutron Irradiation Facilities (PIF & NIF) providing low-intensity energetic proton and neutron beams to simulate radiation exposures for accelerated testing of electronics in space, air, or ground environments. For aerospace and electronics manufacturers.
  • ARTMS QUANTM Irradiation System Technology enabling hospitals to use existing medical cyclotrons for production of medical isotopes including Technetium-99m, Gallium-68, Copper-64, and Zirconium-89 for diagnostic imaging. For hospitals with medical cyclotrons and radiopharmaceutical manufacturers.
  • Ideon Muon Tomography Platform World-first discovery platform using cosmic-ray muon tomography with proprietary detectors, imaging systems, and AI to provide subsurface imaging up to 1 km depth for mineral exploration. For mining and mineral exploration companies.
  • Micromatter Target Foils Thin carbon foils, accelerator target foils, and X-ray fluorescence calibration standards with applications in air quality monitoring, trace element detection, and particle accelerators. For research labs and accelerator operators.
  • IKOMED AI-Guided X-ray Systems AI-guided X-ray shuttering system protecting patients and medical staff during minimally-invasive procedures, and in-development device for emphysema treatment using radiofrequency. For hospitals and surgical centers.
  • D-Pace Accelerator Components Beamline systems, beam diagnostic devices, and ion sources for research, industrial, and commercial accelerator systems, providing H-, D-, C2-, and other ions. For accelerator manufacturers and operators.
  • Canadian Medical Isotope Ecosystem (CMIE) Development Fund Nation-wide initiative co-led with Centre for Probe Development and Commercialization, backed by up to $35M from Strategic Innovation Fund to unite stakeholders and accelerate medical isotope technology development and commercialization through the CMIE Development Fund. For Canadian startups, research institutions, and industry partners in medical isotopes.
  • Ultra-fast Neutron Spectrometer System Ultra-fast neutron spectrometer system developed with General Fusion to measure plasma temperatures at fusion conditions over 100 million degrees Celsius, tagging neutron interactions every nanosecond. For fusion energy developers.

Quantifiable outcome

  • 5 successful spin-off companies created with $52M in financing raised
  • +3 more outcomes

Companies that use TRIUMF Innovations

Customer profile

Named customers6 records

Segments6 records

Ideal customer profiles5 records

TRIUMF Innovations technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability4 records

Feature4 records

TRIUMF Innovations partnerships and signals

Strategic signal

Partnerships

18 partnerships are on record, tiered strategic, minor, flagship and core.

  • General FusionstrategicStrategic or Co-development Partner · 27 March 2024NSERC Alliance grant collaboration to develop ultra-fast neutron spectrometer system for General Fusion's LM26 fusion demonstration machine. $800,000 over four years to measure plasma temperatures at fusion conditions exceeding 100 million degrees Celsius.
  • Simon Fraser UniversityminorStrategic or Co-development Partner · 27 March 2024Partner in neutron spectrometer project with General Fusion, designing and implementing a dedicated neutron test facility at TRIUMF.
  • Université de SherbrookeminorStrategic or Co-development Partner · 27 March 2024Developing and fabricating new Canadian single photon detection technology for the upgraded neutron spectrometer system to be installed on General Fusion's near-commercial machine.
  • Telix PharmaceuticalsflagshipStrategic or Co-development Partner · 11 March 2024Telix Pharmaceuticals acquired ARTMS Inc. for $82.5M USD, including ARTMS' advanced cyclotron-based isotope production platform, manufacturing plant, and stockpile of ultra-pure rare metals. This is the largest acquisition of a TRIUMF spin-off company.
  • Centre for Probe Development and Commercialization (CPDC)coreStrategic or Co-development Partner · 27 June 2023Co-leading the Canadian Medical Isotope Ecosystem (CMIE), a national platform backed by $35 million from the Strategic Innovation Fund. CMIE aims to advance medical isotope production, R&D investment, collaboration, technology adoption, and training to enable Canada to lead in medical isotope innovation.
  • Bruce PowercoreStrategic or Co-development Partner · 27 June 2023CMIE partner providing infrastructure and support for medical isotope production and development in Canada.
  • McMaster UniversitycoreStrategic or Co-development Partner · 27 June 2023CMIE partner with McMaster Nuclear Reactor as part of national platform to accelerate medical isotope development in Canada.
  • Dual FluidstrategicStrategic or Co-development Partner · 10 March 2023MOU with Canadian-German nuclear technology company to advance Small Modular Reactor (SMR) development based on Dual Fluid technology. Collaboration leverages TRIUMF's Proton and Neutron Irradiation Facilities and metallurgical testing capabilities.
  • Fusion PharmaceuticalscoreStrategic or Co-development Partner · 16 December 2020Collaboration for development, production, and supply of actinium-225. Fusion provides funding for TRIUMF to upgrade Ac-225 production infrastructure; receives preferred access and pricing to the resulting isotope for use in their radiopharmaceutical development.
  • Centre for Drug Research and Development (CDRD)coreStrategic or Co-development Partner · 2 April 2019Partnership to advance and commercialize promising research in novel radiopharmaceuticals. Combines R&D, manufacturing, and commercialization strengths to develop innovative personalized cancer treatments using targeted alpha therapy.
  • Canadian Nuclear Laboratories (CNL)coreStrategic or Co-development Partner · 27 September 2018Strategic partnership for production of actinium-225, a rare medical isotope with potential for groundbreaking cancer therapies. TRIUMF produces Ac-225 using its high-energy cyclotron; CNL processes it at Chalk River Laboratories. Successfully completed first joint production run in October 2019.
  • GE HealthcarecoreStrategic or Co-development Partner · 10 September 2017ARTMS partnered with GE Healthcare around the QUANTM99 Irradiation System for radioisotope production. Partnership includes installation of Europe's first QUANTM system and research into expanding isotopes on GE's PETtrace 800 platform of medical cyclotrons.
  • BWXT MedicalcoreStrategic or Co-development PartnerCommercial agreements for production and supply of actinium-225 ('the rarest drug on earth') to researchers and patients around the world.
  • ImaginAbminorStrategic or Co-development PartnerARTMS partnered with ImaginAb for innovative manufacture of 89Zr CD8 ImmunoPET agent using ARTMS' high-power technology to enhance production of ImaginAb's proprietary antibody.
  • POINT BiopharmaminorStrategic or Co-development PartnerARTMS collaboration with POINT Biopharma and Canadian Molecular Imaging Probe Consortium for Health Canada submission on Gallium-68 production.
  • Canadian Nuclear Isotope CouncilstrategicStrategic or Co-development PartnerTRIUMF joined CNIC to strengthen national capacity in radioisotope and radiopharmaceutical research and education, and to advance benefits of medical isotopes in diagnosing and treating life-threatening illnesses.
  • Buckley SystemsminorStrategic or Co-development PartnerElectromagnet manufacturer purchased 50% stake in D-Pace in 2014, enabling collaboration that has developed and commercialized approximately a dozen new products for the particle accelerator market.
  • University of British ColumbiacoreStrategic or Co-development PartnerTRIUMF is hosted on UBC campus; partnered with UBC and BC Cancer for Institute for Advanced Medical Isotopes (IAMI) development. TRIUMF is a joint venture owned by 21 member universities.

Scale indicators17 records

Recent moves12 records

Expansion highlights6 records

TRIUMF Innovations competitors and assessment

Company assessment

Direct peers

  • Canadian Nuclear Laboratories: Canada's federal nuclear science laboratory and a core strategic partner on Ac-225 production. CNL operates Chalk River Laboratories and collaborates with TRIUMF on actinium-225 processing — a comparable government nuclear research entity engaged in isotope production and nuclear materials R&D.
  • ARTMS Inc. (Telix Pharmaceuticals): TRIUMF Innovations' largest spin-off, founded by TRIUMF scientists, commercializing the QUANTM Irradiation System for cyclotron-based medical isotope production. Acquired by Telix Pharmaceuticals in March 2024 for $82.5M USD; provides the closest internal benchmark for TI's commercialization outcomes.
  • Ideon Technologies: TRIUMF spin-off commercializing cosmic-ray muon tomography with AI for subsurface mineral exploration. Directly comparable as a TI-incubated company demonstrating the same commercialization model applied to a non-medical vertical.
  • SHINE Medical Technologies: U.S.-based medical isotope producer using alternative production routes (fusion-based neutron generators) to address Tc-99m and other isotope shortages. Directly comparable mission — solving medical isotope supply chain vulnerability — and a direct competitor to TI/ARTMS technology.
  • NorthStar Medical Radioisotopes: U.S. commercial medical isotope producer focused on non-uranium-based Mo-99/Tc-99m production. Directly comparable as a privately-held commercial-stage medical isotope producer targeting the same supply-chain-replacement opportunity that ARTMS was built to address.

Broad incumbents

  • Telix Pharmaceuticals: Global radiopharmaceutical company and acquirer of ARTMS. While much larger and focused on finished radiopharmaceuticals rather than isotope production technology, Telix represents the strategic acquirer/customer archetype that TI's spin-offs increasingly interact with as commercial-stage entities.
  • GE HealthCare: Global medical imaging and cyclotron manufacturer; ARTMS' QUANTM system integrates onto GE's PETtrace 800 platform, making GE both partner and incumbent competitor with substantially greater scale in PET/SPECT imaging infrastructure.
  • IBA (Ion Beam Applications): Belgian global leader in cyclotron manufacturing, proton therapy, and radioisotope production. Operates in the same isotope production and accelerator technology space as TRIUMF/D-Pace but with substantially greater commercial scale and global footprint.
  • BWX Technologies: U.S. nuclear technology manufacturer with a medical isotopes division (BWXT Medical) that is a commercial partner of TRIUMF Innovations on Ac-225 supply. Comparable as an incumbent in nuclear medicine isotopes and a customer/competitor in sealed source manufacturing.

Regional players

  • Cyclotek: Australian radiopharmaceutical manufacturer producing PET and SPECT tracers using cyclotrons. Comparable as a privately-held regional radiopharma producer, though operating in a different geography from TRIUMF Innovations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

TRIUMF Innovations social profiles

Digital presence

TRIUMF Innovations compliance and trust

Trust signal

Compliance1 record

TRIUMF Innovations financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TRIUMF Innovations leadership team

Management profile

Number of profiles

Profiles4 records

TRIUMF Innovations subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

TRIUMF Innovations funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TRIUMF Innovations M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TRIUMF Innovations

What does TRIUMF Innovations do?

TRIUMF Innovations commercializes particle-accelerator-based technologies developed at TRIUMF, Canada's national particle accelerator laboratory. It does so through technology licensing, spin-off company creation and equity oversight, fee-based irradiation and medical isotope production services using TRIUMF's cyclotrons and Proton/Neutron Irradiation Facilities, and the Canadian Medical Isotope Ecosystem (CMIE) national platform that channels federal funding into radiopharmaceutical development. Its customer base consists of radiopharmaceutical companies, hospitals with medical cyclotrons, aerospace and electronics firms needing radiation testing, mining exploration companies, and fusion energy developers.

Is TRIUMF Innovations a public or private company?

TRIUMF Innovations is a private company. It is classified as state government owned and is currently operating.

When was TRIUMF Innovations founded?

TRIUMF Innovations was founded in 2008. It employs 1 to 10 people.

Where is TRIUMF Innovations based?

TRIUMF Innovations is headquartered in Vancouver, Canada, in the North America region.

How does TRIUMF Innovations make money?

Five revenue lines are on record. Technology Licensing and IP Management is the primary driver. The others are company Creation and Spin-offs, industry Partnerships and Collaborations, irradiation Testing Services and federal and Provincial Funding.

Who are TRIUMF Innovations's main competitors?

Direct peers on record are Canadian Nuclear Laboratories, ARTMS Inc. (Telix Pharmaceuticals), Ideon Technologies, SHINE Medical Technologies and NorthStar Medical Radioisotopes. Broad incumbents are Telix Pharmaceuticals, GE HealthCare, IBA (Ion Beam Applications) and BWX Technologies. Cyclotek is listed as a regional player.

Does TRIUMF Innovations have an API?

No public API is recorded for TRIUMF Innovations.

What industry is TRIUMF Innovations in?

TRIUMF Innovations's product category is Technology Commercialization and Particle Accelerator-Based Research Services. Its primary akta.pro industry code is HLAIAGAD, Radioisotope Production (Reactor/Cyclotron/Gamma), with a secondary code of EUAKAIAA, Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.). Its NAICS code is 54138 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales